Catalyst Wire Dossier Catalyst Wire Dossier

Tinengotinib

tinengotinib · TransThera Sciences (Nanjing), Inc.
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for Tinengotinib, covering 2024-04-26 to 2026-03-27. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment [Phase 2]

See pricing